NITI Aayog Sets Up Panel to Transform AIIMS New Delhi

The committee will evaluate existing systems and propose comprehensive reforms with defined timelines, according to NITI Aayog’s annual report for 2024-25.

NITI Aayog has established a committee led by its member, Dr. V K Paul, to develop a strategic roadmap for transforming the All India Institute of Medical Sciences (AIIMS) in New Delhi. The committee will evaluate existing systems and propose comprehensive reforms with defined timelines, according to NITI Aayog’s annual report for 2024-25.

Focus Areas: Streamlining Systems and Financial Sustainability

The committee has been tasked with identifying measures to enhance patient management, develop Key Performance Indicators (KPIs) for clinical, academic, and research excellence, and improve governance mechanisms. It will also explore strategies to ensure financial sustainability and self-sufficiency in AIIMS operations.

"The mandate includes examining AIIMS’ current framework and recommending reforms that enhance governance, efficiency, and financial prudence," the report stated. The committee will also focus on increasing transparency and optimizing the institution’s role in delivering high-quality healthcare.

Additionally, NITI Aayog, in collaboration with the CSEP Research Foundation, has been studying global models of Universal Health Coverage (UHC) to derive insights applicable to India's healthcare system. "The draft paper proposes a multi-faceted approach addressing both supply-side and demand-side financing to improve healthcare accessibility, affordability, and quality," the report added.

Efforts to Improve Drug Accessibility for Rare Diseases

In a bid to make essential medicines more affordable, NITI Aayog has taken steps to fast-track the production of indigenous drugs for rare diseases. According to the report, four drugs have already been introduced at prices significantly lower than imported alternatives—ranging from 1/60th to 1/100th of the original cost.

"Four more drugs are in the approval pipeline and are expected to be available by the end of the year," the report noted. Additionally, a syrup formulation of Hydroxyurea for managing Sickle Cell Disease is also undergoing regulatory review.

The Ayushman Bharat scheme, launched in 2018, has played a critical role in reducing patients' financial burdens by integrating primary, secondary, and tertiary healthcare services. The government aims to strengthen these initiatives further through policy interventions and stakeholder consultations.